nirmatrelvir antivir medic develop pfizer act oral activ clike proteas inhibitor part nirmatrelvirritonavir combin sell brand name paxlovid coronavir proteas cleav multipl site viral polyprotein usual glutamin residu earli work relat human rhinovirus show flexibl glutamin side chain could replac rigid pyrrolidon drug far develop prior sar cov pandem diseas includ sar util target cl proteas real world set first demonstr gc prodrug gc use treat previous lethal cat coronavirus diseas felin infecti periton caus felin coronavirus nirmatrelvir analog gc aldehyd coval cystein acceptor replac nitril nirmatrelvir develop modif earli clinic candid lufotrelvir also coval proteas inhibitor warhead phosphat prodrug hydroxyketon lufotrelvir need administ intraven limit use hospit set stepwis modif tripeptid protein mimet lead nirmatrelvir suitabl oral administr key chang includ reduct number hydrogen bond donor number rotat bond introduc rigid bicycl noncanon amino acid mimic leucin residu find earli inhibitor residu previous use synthesi boceprevir tertleucin abbrevi tle use posit nirmatrelvir identifi first optim noncanon amino acid potenti drug target sarscov clike proteas use combinatori chemistri hybrid combinatori substrat librari technolog full detail synthesi nirmatrelvir first publish scientist pfizer penultim step synthet homochir amino acid coupl homochir amino amid use watersolubl carbodiimid edci coupl agent result intermedi treat burgess reagent dehydr amid group nitril product nirmatrelvir coval inhibitor bind direct catalyt cystein cys residu cystein proteas enzym copackag medic nirmatrelvirritonavir ritonavir serv slow metabol nirmatrelvir via cytochrom enzym inhibit therebi increas circul concentr main drug effect also use hiv therapi ritonavir use combin anoth proteas inhibitor similar enhanc pharmacokinet novemb pfizer sign licens agreement unit nationsback medicin patent pool allow nirmatrelvir manufactur sell countri pfizer state agreement allow local medicin manufactur produc pill goal facilit great access global popul howev deal exclud sever countri major covid outbreak includ brazil china russia argentina thailand februari pfizer begin first phase trial pf nirmatrelvir